New industrial orders in Germany increased month on month in December 2021

Big Pharma CCHT’s Domination Unlikely to Fade Soon Despite Official Bulk Buying

The producer of long-acting growth hormone acupunctures, vaccines and other drugs, looks set to offset the effects of so-called “centralized procurement” on its product prices with more aggressive expansion into private hospitals. So far, its monopoly appears unshakable, but with more competitors upping the stakes, how long will it last?

Disruptive Competitiveness: The Missing Piece in the Sovereignty Puzzle

Europe’s sovereignty depends on its ability to innovate and compete. For Chinese companies, building a European presence starts with strong local roots.

Sino Biopharm and Boehringer Ingelheim Sign Option and License Deal for Six Cancer Programs

Sino Biopharmaceutical（中国生物制药）and Boehringer Ingelheim（勃林格殷格翰）announced an option and license agreement on November 4 covering six preclinical cancer programs. Sino Biopharm will receive USD 358 million in upfront and near-term payments and may receive up to USD 7 billion in additional option, development, regulatory and commercial milestone payments.

Wantai Launches Nine-Valent HPV Vaccine Cecolin 9 in Thailand

Wantai Biological（万泰生物）said on November 2 that its nine-valent HPV vaccine, Cecolin 9（馨可宁9）, had launched in Thailand. The product was jointly developed by its subsidiary Xiamen Innovax Biotech（厦门万泰沧海生物技术有限公司）and Xiamen University（厦门大学）.

From Paris to Shanghai: The Same Project, Two Different Views of Time

In Europe-China industrial cooperation, misunderstandings often start with time. Chinese companies may see European decision-making as slow. European companies may see Chinese execution as rushed. Yet very often, neither side is wrong. They are responding rationally to different ecosystems, different levels of system interdependence and different views of risk.